The Advisory Board Co. (NASDAQ:ABCO) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,094,901 shares, an increase of 33.3% from the October 31st total of 1,571,684 shares. Currently, 5.3% of the shares of the stock are short sold. Based on an average daily volume of 667,060 shares, the days-to-cover ratio is currently 3.1 days.

The Advisory Board (NASDAQ:ABCO) opened at 36.85 on Tuesday. The Advisory Board has a 1-year low of $18.87 and a 1-year high of $54.83. The company has a 50-day moving average of $38.72 and a 200 day moving average of $38.73. The stock’s market cap is $1.48 billion.

The Advisory Board (NASDAQ:ABCO) last issued its quarterly earnings results on Tuesday, November 1st. The company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by $0.12. The firm earned $200.50 million during the quarter, compared to the consensus estimate of $203.35 million. The Advisory Board had a negative net margin of 5.77% and a positive return on equity of 11.28%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 earnings per share. Analysts predict that The Advisory Board will post $1.83 EPS for the current year.

In other The Advisory Board news, insider Hoose Mary Van sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $36.98, for a total value of $73,960.00. Following the completion of the transaction, the insider now directly owns 37,386 shares in the company, valued at $1,382,534.28. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert W. Musslewhite sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $43.09, for a total transaction of $236,995.00. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the stock. American Capital Management Inc. raised its stake in shares of The Advisory Board by 6.6% in the second quarter. American Capital Management Inc. now owns 764,915 shares of the company’s stock worth $27,070,000 after buying an additional 47,235 shares during the period. Stoneridge Investment Partners LLC bought a new stake in The Advisory Board during the second quarter worth about $2,287,000. Royal Bank of Canada increased its stake in The Advisory Board by 6.0% in the first quarter. Royal Bank of Canada now owns 1,252,911 shares of the company’s stock worth $40,406,000 after buying an additional 70,769 shares in the last quarter. Princeton Alpha Management LP bought a new stake in The Advisory Board during the second quarter worth about $236,000. Finally, Douglas Lane & Associates LLC increased its stake in The Advisory Board by 31.6% in the second quarter. Douglas Lane & Associates LLC now owns 683,294 shares of the company’s stock worth $24,182,000 after buying an additional 164,025 shares in the last quarter.

A number of equities analysts have weighed in on ABCO shares. Zacks Investment Research upgraded shares of The Advisory Board from a “hold” rating to a “strong-buy” rating and set a $48.00 price target for the company in a research report on Monday, August 1st. Cantor Fitzgerald restated a “hold” rating on shares of The Advisory Board in a research report on Friday, August 19th. Credit Suisse Group AG restated a “buy” rating and set a $50.00 target price on shares of The Advisory Board in a research report on Friday, September 16th. William Blair restated an “outperform” rating on shares of The Advisory Board in a research report on Tuesday, September 27th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and set a $49.00 target price (up previously from $45.00) on shares of The Advisory Board in a research report on Wednesday, September 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $43.25.

TRADEMARK VIOLATION NOTICE: “The Advisory Board Co. (ABCO) Short Interest Up 33.3% in November” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2016/11/29/the-advisory-board-co-abco-short-interest-up-33-3-in-november.html.

The Advisory Board Company Profile

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.

5 Day Chart for NASDAQ:ABCO

Receive News & Stock Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related stocks with our FREE daily email newsletter.